539 related articles for article (PubMed ID: 25359881)
1. Investigating the role of angiogenesis in systemic lupus erythematosus.
Liu J; Wang X; Yang X; Yan Q; Wang S; Han W
Lupus; 2015 May; 24(6):621-7. PubMed ID: 25359881
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
[TBL] [Abstract][Full Text] [Related]
3. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus.
Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
Lupus; 2002; 11(6):348-55. PubMed ID: 12139372
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significance.
Zhou L; Lu G; Shen L; Wang L; Wang M
Biomed Res Int; 2014; 2014():627126. PubMed ID: 24511540
[TBL] [Abstract][Full Text] [Related]
5. Selected angiogenic cytokines in systemic lupus erythematosus patients.
Hrycek A; Janowska J; Cieślik P
Autoimmunity; 2009 Aug; 42(5):459-66. PubMed ID: 19811263
[TBL] [Abstract][Full Text] [Related]
6. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic activity in sera of patients with systemic lupus erythematosus.
Sakly N; Mirshahi P; Ducros E; Soria J; Ghedira I; Mirshahi M
Lupus; 2009 Jul; 18(8):705-12. PubMed ID: 19502266
[TBL] [Abstract][Full Text] [Related]
8. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
10. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
11. Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus.
Robak E; Kierstan M; Cebula B; Krawczynska A; Sysa-Jedrzejowska A; Wierzbowska A; Smolewski P; Robak T
Lupus; 2009 Apr; 18(4):332-41. PubMed ID: 19276301
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities.
Kuryliszyn-Moskal A; Klimiuk PA; Sierakowski S; Ciołkiewicz M
Arch Immunol Ther Exp (Warsz); 2007; 55(3):179-85. PubMed ID: 17557150
[TBL] [Abstract][Full Text] [Related]
13. Soluble Flt-1, Placental Growth Factor, and Vascular Endothelial Growth Factor Serum Levels to Differentiate Between Active Lupus Nephritis During Pregnancy and Preeclampsia.
de Jesús GR; Lacerda MI; Rodrigues BC; Dos Santos FC; do Nascimento AP; Cristóvão Porto L; de Jesús NR; Levy RA; Klumb EM
Arthritis Care Res (Hoboken); 2021 May; 73(5):717-721. PubMed ID: 32583963
[TBL] [Abstract][Full Text] [Related]
14. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
Robak E; Sysa-Jedrzejewska A; Robak T
Mediators Inflamm; 2003 Oct; 12(5):293-8. PubMed ID: 14760936
[TBL] [Abstract][Full Text] [Related]
16. Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations.
Moneib HA; Salem SA; Aly DG; Khedr HT; Wafaey HA; Hassan HE
J Dermatol; 2012 Jan; 39(1):52-7. PubMed ID: 21950586
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
Heshmat NM; El-Kerdany TH
Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298
[TBL] [Abstract][Full Text] [Related]
19. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
20. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
